(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Terapia génica y Hepatología > Inmunología terapia génica > DA - CIMA - Terapia génica y Hepatología - Inmunología terapia génica - Artículos de revista >

Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients
Autor(es) : Alfaro, C. (Carlos)
Perez-Gracia, J.L. (José Luis)
Suarez, N. (Natalia)
Rodriguez, J. (Javier)
Fernandez-Sanmamed, M. (Miguel)
Sangro, B. (Bruno)
Martin-Algarra, S. (Salvador)
Calvo, A. (Alfonso)
Redrado, M. (Miriam)
Agliano, A. (Alice)
Gonzalez, A. (Álvaro)
Rodriguez, I. (Inmaculada)
Bolaños, E. (Elixabet)
Hervas-Stubbs, S. (Sandra)
Perez-Calvo, J. (Javier)
Benito, A. (Alberto)
Peñuelas, I. (Iván)
Vigil, C. (Carmen)
Richter, J.A. (José Ángel)
Martinez-Forero, I. (Iván)
Melero, I. (Ignacio)
Palabras clave : Metastatic Cancer
Clinical Trial
Dendritic Cells
Cyclophosphamide
Fecha incorporación: 2011
Editorial : American Association of Immunologists
Versión del editor: http://www.jimmunol.org/content/187/11/6130
ISSN: 1550-6606
Cita: Alfaro C, Perez-Gracia JL, Suarez N, Rodriguez J, Fernandez de Sanmamed M, Sangro B, et al. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J Immunol 2011 Dec 1;187(11):6130-6142.
Resumen
Twenty-four patients with metastatic cancer received two cycles of four daily immunizations with monocyte-derived dendritic cells (DC). DC were incubated with preheated autologous tumor lysate and subsequently with IFN-α, TNF-α, and polyinosinic:polycytidylic acid to attain type 1 maturation. One DC dose was delivered intranodally, under ultrasound control, and the rest intradermally in the opposite thigh. Cyclophosphamide (day -7), GM-CSF (days 1-4), and pegIFN alpha-2a (days 1 and 8) completed each treatment cycle. Pretreatment with cyclophosphamide decreased regulatory T cells to levels observed in healthy subjects both in terms of percentage and in absolute counts in peripheral blood. Treatment induced sustained elevations of IL-12 in serum that correlated with the output of IL-12p70 from cultured DC from each individual. NK activity in peripheral blood was increased and also correlated with the serum concentration of IL-12p70 in each patient. Circulating endothelial cells decreased in 17 of 18 patients, and circulating tumor cells markedly dropped in 6 of 19 cases. IFN-γ-ELISPOT responses to DC plus tumor lysate were observed in 4 of 11 evaluated cases. Tracing DC migration with [(111)In] scintigraphy showed that intranodal injections reached deeper lymphatic chains in 61% of patients, whereas with intradermal injections a small fraction of injected DC was almost constantly shown to reach draining inguinal lymph nodes. Five patients experienced disease stabilization, but no objective responses were documented. This combinatorial immunotherapy strategy is safe and feasible, and its immunobiological effects suggest potential activity in patients with minimal residual disease. A randomized trial exploring this hypothesis is currently ongoing.
Enlace permanente: http://hdl.handle.net/10171/20367
Aparece en las colecciones: DA - CIMA - Oncología - Nuevas dianas terapéuticas - Artículos de revista
DA - Medicina - Medicina Interna - Artículos de revista
DA - CIMA - Terapia génica y Hepatología - Inmunología terapia génica - Artículos de revista

Ficheros en este registro:

No hay ficheros asociados a este ítem.

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.